share_log

博晖创新(300318.SZ):控股孙公司终止相关冻干人用狂犬病疫苗(无血清Vero细胞)项目合作合同及药物临床试验

beijing bohui innovation biotechnology group(300318.SZ): 子会社の持分を買い取り、関連する冷凍乾燥ヒト用狂犬病ワクチン(セリン 0 細胞中に血清がない)プロジェクトの協力契約と薬物臨床試験を終了しました

Gelonghui Finance ·  09/24 06:06

beijing bohui innovation biotechnology group (300318.SZ) announced that its subsidiary, bohui biopharmaceuticals co., ltd. (formerly known as zhongke biopharmaceuticals co., ltd., hereinafter referred to as 'langfang bohui'), and chengdu biotech corporation signed a 'project cooperation contract' in january 2020, under which chengdu biotech completed preclinical research on freeze-dried human rabies vaccine (serum-free vero cells) and jointly applied for approval. in july 2020, the vaccine obtained the 'notice of drug clinical trial approval' issued by the national medical products administration. in september 2024, langfang bohui, chengdu biotech, and other related parties signed a 'supplementary agreement' to the 'project cooperation contract', agreeing that after meeting the conditions, the 'project cooperation contract' signed by both parties in january 2020 would be terminated, and the clinical trial of freeze-dried human rabies vaccine (serum-free vero cells) developed by both parties would be terminated. recently, langfang bohui received full compensation from chengdu biotech, and the 'project cooperation contract' was officially terminated.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする